AM-0902 is a potent and selective Transient Receptor Potential A1 (TRPA1) Antagonist Demonstrating Potent in Vivo Activity with pharmacokinetic properties allowing for >30-fold coverage of the rat TRPA1 IC50 in vivo. AM-0902 showed rTRPA1 45Ca2+ Flux IC50=0.071 microM and hTRPA1 45Ca2+ Flux IC50=0.131 microM. AM-0902 demonstrated dose-dependent inhibition of AITC-induced flinching in rats, validating its utility as a tool for interrogating the role of TRPA1 in in vivo pain models.